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Food allergy has grown in rapidly in prevalence, currently affecting 5% of adults and 8% of children.
Management strategy is currently limited to 1) food avoidance and 2) carrying and using rescue intra-
muscular epinephrine/adrenaline and oral antihistamines in the case of accidental ingestion; there is no
FDA approved treatment. Recently, oral, sublingual and epicutaneous immunotherapy have been
developed as active treatment of food allergy, though none have completed phase 3 study. Efﬁcacy and
safety studies of immunotherapy have been variable, though there is clearly signal that immunotherapy
will be a viable option to desensitize patients. The use of bacterial adjuvants, anti-IgE monoclonal an-
tibodies, and Chinese herbal formulations either alone or in addition to immunotherapy may hold
promise as future options for active treatment. Active prevention of food allergy through early intro-
duction of potentially offending foods in high-risk infants will be an important means to slow the rising
incidence of sensitization.
Copyright © 2016, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Background
An allergic reaction to food is deﬁned as an IgE mediated reac-
tion to ingestion of a speciﬁc food. Symptoms of food allergy may
include abdominal pain, vomiting, urticaria and anaphylaxis. The
prevalence of food allergy has risen considerably in recent years,
now estimated to be 5% in adults and 8% in children, with some
regional variability.1e5 Estimates of growth in incidence of food
allergy range from 18% from 1997 to 2007, to a doubling over the
past decade.3,6 With the incidence of food allergy rising so quickly,
there has been an intensiﬁcation of research efforts directed toward
ﬁnding a treatment and eventually a cure.
Management of food allergy currently consists of strict and
careful food avoidance, while keeping emergency treatment
available at all times.7 If an allergenic food is ingested, this is treatedd Immunology, University of
ilding, CB# 7220, Chapel Hill,
u (A.K. Kobernick).
ety of Allergology.
rgology. Production and hosting by Elsewith intramuscular epinephrine/adrenaline or oral antihistamines
(or occasionally systemic corticosteroids), depending on the age of
the patient, severity of the reaction and the amount ingested.
Without a pharmacologic option for active treatment, families are
forced to remain ever-vigilant, closely monitoring food labels,
taking caution with food at social gatherings and carrying an
epinephrine/adrenaline auto-injector at all times. The stressful
psychological effect that food allergy has on patients and their
families is quite apparent, and quality of life is diminished.8 Fam-
ilies have reason to be stressed, as accidental ingestion occurs
frequently9: one study reported that up to 75% of patients with
peanut allergy will accidentally consume peanuts.10 Furthermore,
treatment of accidental ingestions with an epinephrine/adrenaline
auto-injector is anxiety provoking and perceived by patients and
families as challenging.11 The anxiety surrounding the potential for
a severe reaction any time food is consumed signiﬁcantly di-
minishes quality of life for patients and their families.
Food allergy is currently treated by a combination of speciﬁc
food avoidance, provision of emergency treatment, and moni-
toring. Speciﬁcally, patients are told to speciﬁcally avoid the food
to which they're allergic, which can be challenging given thevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
Table 2
Tolerance and sustained unresponsiveness induced by oral immunotherapy (OIT),
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patient is accidentally exposed to an offending food, they are
treated emergently with intramuscular epinephrine/adrenaline
and oral antihistamines, as described above. Monitoring involves
frequent food-speciﬁc IgE and skin prick testing. An oral food
challenge (OFC) may be attempted as a patient develops a pattern
that may be consistent with tolerance. The OFC represents the
gold standard for diagnosis of food allergy, since some patients
will spontaneously develop tolerance to previously offending
foods over time.
Although food allergy is a commonly encountered problem,
active treatment toward desensitization has been limited to the
research setting. In this paper, we deﬁne desensitization as an in-
crease in threshold reactivity for a particular subject, and sustained
tolerance as retention of that increased reactivity threshold for
months to years without further treatment. Subcutaneous immu-
notherapy (SCIT) for peanut allergy was studied in the 1990s,
though in this trial, the rate of severe reactions was unacceptably
high.12 Since then, oral, sublingual, and epicutaneous immuno-
therapy, have been described in a number of trials, as have re-
combinant vaccines, immunobiologics, bacterial adjuvants and
herbal therapeutics (Table 1).
The goal associated with food immunotherapy remains
controversial. While some feel the goal should be to induce
desensitization and sustained unresponsiveness, others feel that a
small amount of tolerance e allowing a patient to tolerate an
accidental bite of an offending food, for example e is clinically and
emotionally signiﬁcant. In this review, we highlight trials that look
at both types of endpoints. Food allergy is a common problem
resulting in signiﬁcant physical, emotional and psychiatric
morbidity and mortality; it is therefore necessary to ﬁnd a safe,
efﬁcacious management strategy.
Allergen speciﬁc therapies
Subcutaneous immunotherapy
Subcutaneous immunotherapy was employed in 1992 for
desensitization of peanut allergic subjects.13 Patients in this study
completed an initial rush schedule followed by maintenance
dosing. After promising initial results, the study was terminated
early due to a fatal reaction. The fatality occurred following a
formulation error in the pharmacy, wherein a placebo-treated pa-
tient received a maintenance dose of immunotherapy.
Since subcutaneous immunotherapy had been so successful in
treating aeroallergy, the technique was reattempted for active
treatment of food allergy, this time in an adult study.12 Unfortu-
nately, a very high rate of systemic reaction occurred: 23% of pa-
tients during rush buildup and 39% during maintenance doing.
Recombinant proteins for use in SCIT, thought to potentially
enhance safety, was reported by Zuidmeer-Jongejan et al. in 2012.14
From this group, we can expect to see development of novel pro-
teins representing the active allergens in peach and ﬁsh, whichmay
be better tolerated than the unaltered food. Human studies in this
arena have not been reported to date.Table 1
Change in biomarkers after active treatment with immunotherapy.
Biomarker Change after immunotherapy
Skin prick reactivity Y
Allergen speciﬁc IgE Y (after initial increase)
Allergen speciﬁc IGG4 [
Basophil activation YOral immunotherapy
Oral immunotherapy (OIT) involves exposing patients to esca-
lating doses of the offending food with the goal of inducing
desensitization or sustained unresponsiveness (Tables 1e4). OIT
has primarily been attempted in the research setting and is not FDA
approved. A typical OIT protocol involves an entry challenge to
establish clinical reactivity, followed by escalating doses of the
offending food until a pre-speciﬁed maintenance dose is achieved
for a pre-speciﬁed amount of time. If this maintenance dose is
successfully achieved, the patient is said to be desensitized. After
that, the maintenance dose may be discontinued for a pre-speciﬁed
amount of time and the patient rechallenged with the offending
food. If the subject does not react, he or she has been said to have
achieved sustained tolerance.
Side effects of OIT continue to be elucidated, and most
commonly include abdominal pain and oral pruritus (75%, Table 3).
More severe side effects such as eosinophilic esophagitis (2.7%) and
severe reactions requiring intramuscular epinephrine/adrenaline
(25% of patients, Table 3) are not uncommon.15e18
The mechanism of action of OIT is postulated to involve mod-
ulation of the immune response (Table 1). Speciﬁcally, a decline in
speciﬁc IgE and concomitant increase in protective IgG4, as well as
induction of basophil activation anergy and increased regulatory T-
cells have been shown.19e21 Mast cells, basophils and neutrophils
are all involved in the anaphylactic response, and are likely modi-
ﬁed by OIT.22 B cell populations associated with food allergy have
been described, along with changes in their IgG4 repertoire
induced by OIT.23
Oral immunotherapy for food allergy has been reported as early
as 1998, thoughmore recent trials have exhibited higher degrees of
control and randomization; these will be reviewed below.24Peanut OIT
While advances in OIT continue rapidly, there is still no FDA-
approved treatment available, and a recent Cochrane review re-
ports uncertainty associated with this approach.25 In a 2009 land-
mark peanut OIT randomized controlled trial (RCT), children with
peanut allergy underwent an OIT protocol including initial day
escalation, buildup and maintenance phases, and then OFC.26 This
systematic approach is typical of most RCTs for food allergy.
Twenty-nine subjects completed the protocol, 27 of whom suc-
cessfully ingested 3900 mg of peanut protein (equivalent to about
16 peanuts) following treatment. Mechanistic data reported
included diminished skin prick test reactivity, peanut speciﬁc IgE,
and basophil activation in the treatment group, with peanut-
speciﬁc IgG4 signiﬁcantly increasing.
In 2011, peanut OIT was further explored in another RCT,
examining 28 subjects aged 1e16 years.27 All 16 children in the
treatment arm tolerated 5000 mg of peanut protein (roughly 20
peanuts) after OIT. Mechanistic data was of similar pattern to thatsublingual immunotherapy (SLIT), and epicutaneous immunotherapy (EPIT).
Type of IT Tolerance Sustained unresponsiveness
OIT >60% 10e50%
SLIT 10% (70% show modest
level of tolerance)
Minimal
EPIT Modestly induced
in 28e50%
None demonstrated
to date
Tolerance is deﬁned by being able to tolerate the food in a typical diet. Sustained
unresponsiveness is deﬁned as being able to tolerate the food in a typical diet after
immunotherapy has been terminated.
Table 3
Summary of adverse events reported in oral immunotherapy (OIT), sublingual
immunotherapy (SLIT), and epicutaneous immunotherapy (EPIT).
Type of IT Mild adverse events Serious adverse events
OIT 2e5% of doses,
mostly abdominal
Epinephrine/adrenaline required
in less than 1% of doses,
but up to 24% of patients.
EoE association 2.7%.
SLIT <2% of doses,
mostly oropharyngeal
No severe or anaphylactic
reactions reported.
EPIT 50% of patients,
mostly skin
No severe or anaphylactic
reactions reported.
Table 4
Factors which may improve efﬁcacy and safety of food immunotherapy.
Efﬁcacy: factors which
may improve
Safety: factors which
may improve
 Probiotic adjuvants  Anti-IgE therapy (omalizumab)
 Younger age at initiation of IT  Avoid dosing near exercise or URI
 Lower maintenance dosing
 Selection of patients with low speciﬁc IgE
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ratio of FOXP3-hi expression to FOXP3-intermediate expression
CD4þ CD25þ T-cells was observed at the time of OFC in treated
subjects.
A more recent RCT, the 2014 STOP II trial, was a crossover trial
examining children 7e16 years of age.15 The primary outcome was
desensitization, deﬁned as tolerating 1400 mg of peanut protein,
and this was recorded for 62% of subjects. Quality of life scores
improved overall after OIT, although side effects including nausea
and vomiting were reported in 31 of 39 patients. A systemic reac-
tion requiring intramuscular epinephrine/adrenaline was reported
after one dose in the trial (0.01%).
Desensitization to peanut protein using OIT is clearly possible. A
remaining question is whether, after discontinuing OIT, desensiti-
zation persists. We deﬁne sustained unresponsiveness as persistent
tolerance of the offending allergen after cessation of OIT. In 2014,
Vickery et al. examined the phenotype of patients who exhibited
sustained unresponsiveness after desensitization to peanut protein.
In this protocol, subjects were desensitized to tolerate 4000mg/day
of peanut protein. OIT was then stopped, and onemonth later 12/24
subjects demonstrated sustained unresponsiveness to a 5000 mg
open food challenge.28 Subjects who exhibited sustained unre-
sponsiveness had lower levels at baseline and at ﬁnal OFC of skin
prick test size, peanut-speciﬁc IgE, Ara h 1 IgE, and Ara h 2 IgE,
along with reduced peanut-speciﬁc IgE to total IgE ratio. IgG4 was
not signiﬁcantly different among groups. In patients who exhibited
sustained unresponsiveness, diet was liberalized to incorporate
peanut.
Protocols have been modiﬁed to be shorter, including one in
2015 that reported faster time to maintenance dosing, lower
maintenance dose (2 g peanut protein), and fewer side effects.
Though this was a small study with limited generalizability, similar
efﬁcacy of desensitization was observed.29
Peanut OIT with adjuvant
The use of adjuvants in OIT represents a promising area of
exploration. A 2014 double blinded RCT, examining patients 1e10
years old, reported using peanut OIT combined with a bacterial
adjuvant, the probiotic lactobacillus.30 Among treated patients,
desensitization occurred to 2 g of peanut protein in 89%. The au-
thors examined possible sustained unresponsiveness, and reported
success 2e5 weeks after discontinuation of treatment in 23 of 28patients (82.1%), and in 1 of 28 patients receiving placebo. The
number needed to treat was calculated to be 1.27, treat 9 patients,
and 7 will show sustained unresponsiveness. This study was
limited by the absence of an OIT-only group to show the effect of
the probiotic, and the short time off of OIT until challenge.
A limitation of all OIT studies is a lack of long-term data.
Whether sustained unresponsiveness exists at one or more years is
currently unknown.Future possibilities for peanut OIT
Use of peanut ﬂour has been robustly studied in OIT, and now
alternate formulations are now being examined. A peanut protein
polyphenol edible matrix (tomake peanut allergens less allergenic)
for OIT was examined 2014.31 The study used an ex-vivo assay with
human blood, and examined the effectiveness of the matrix pro-
tein. Compared to unmodiﬁed peanut ﬂour, the edible matrix
incorporating peanut protein was found to trigger less basophil
degranulation.When examined using amousemodel, less mast cell
degranulation was observed. Modiﬁcation or alternate formulation
of peanut protein remains an exciting possibility to increase toler-
ability of OIT.Egg OIT
In a landmark 2012 study, the largest RCT for egg OIT to datewas
reported prospectively in children aged 5e11 years old by Burks
et al.32 Forty children received egg OIT; 55% were desensitized to a
maintenance dose of 2 g egg-white powder at 10 months, and 75%
at 22 months. A 10 g oral food challenge conﬁrmed desensitization.
Of desensitized patients, 28% exhibited sustained unresponsiveness
by completing a 10 g egg powder oral food challenge after dis-
continuing OIT for 2 months.
In 2015, an RCT was reported where a 4-month protocol
desensitized 16 children aged 4e11 to a maintenance dose of 4 g of
egg-white powder followed by egg avoidance to examine sustained
unresponsiveness.33 Among 16 kids aged 4e11 who achieved
desensitization, 31% remained tolerant of egg-white powder after 3
months of avoidance.
Desensitization was reported using increasing home doses of a
liquid hen's egg protein, with a success rate of 80% in achieving
desensitization.34 Modiﬁed protocols requiring OIT dosing as little
as 2e3 times per week have been reported with similar efﬁcacy.35
Rush desensitization has induced tolerance in as little as 5 days.36,37
An area of interest in egg allergy is why some patients react to
food containing any egg, whereas others are able to tolerate egg in
the extensively heated (baked) form. Current studies indicate that
64% of egg allergic patients tolerate extensively heated egg.38 An
area of research, then, is whether extensively heated egg may act as
immunotherapy among patients who tolerate it. In 2012, this
concept was examined in a study where patients tolerant of baked
egg consumed it regularly (mufﬁn or wafﬂe), and 53% of those
patients tolerated low-heat egg after a median of 37months.39 Only
26% of baked-egg restricted patients exhibited similar tolerance.
This study had signiﬁcant limitations, including absence of
randomization, and further studies examining this question are
warranted. Side effects are thought to be signiﬁcant as well; it is
reported that only two-thirds of baked-egg tolerant patients will
regularly eat it due to abdominal pain.40
The use of recombinant proteins such as Gal d 1, 2, 3, and 4 in
egg OIT represents a novel therapeutic option. In a 2015 study,
these proteins were been found to react with egg-allergic patient's
sera, though phase 1 human trials have not been reported.41
Quality of life appears to improve for patients on egg OIT,42 but
side effects are common. These side effects include chronic
abdominal pain and life threatening anaphylaxis.43 Strategies to
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ciﬁc egg IgE, which may be a predictor of safety.44,45
Milk OIT
Cow'smilk (CM) OIT is thought towork by similar mechanism as
other forms of OIT. It has been shown in infants that CM OIT in-
creases protective protein-speciﬁc IgG4.46 Successful desensitiza-
tion using CM OIT was demonstrated in 2008, in a RCT of 60
children.47 In this study, children were randomized to complete an
in-hospital rush protocol followed by maintenance OIT to a
maximum daily dose of 150 mL cow's milk. After one year of OIT,
tolerance of 150 mL of CM was induced in 35% of treated children
versus 5% of untreated. A 2010 study reported a desensitization
protocol with weekly home up-dosing in 15 patients.48 Adverse
events were signiﬁcant in one-third of those patients, with 2 of 15
in the treatment-group dropping out and 3 having immunotherapy
stopped by the study staff.
While many studies have examined OIT in preschool to school
aged children, some researchers believe that younger patients may
be more amenable to desensitization. Martorell et al. studied CM
OIT in 2011 among a population of 60 patients aged 24e36
months.49 This study was an RCT where 30 children were treated
with CM OIT. Among actively treated children, 90% became tolerant
of CM, versus 23% of placebo-treated children. Adverse reactions
were reported at a very high rate this young cohort: 80% of treated
patients, most commonly urticaria-angioedema followed by cough.
Desensitization rates using CM OIT in smaller studies have
ranged from 71 to 80%.50,51 Adverse reactions have been reported in
up to 45.4%e95% of treatment doses, including mild reactions and
local symptoms.51,52 Similar to other forms of OIT, CM IgG4 levels
have been found to increase in patients actively treated.52
Protocols examining SLIT induction followed by OIT have also
been examined. In a study from Keet et al. in 2012, patients were
randomized to receive either SLIT induction followed by OIT versus
SLIT alone.17 While SLIT with OIT was found to be more effective,
more adverse events were observed.
Long term effectiveness of CM OIT remains challenging. Five
years after desensitization with OIT, only about half of patients
successfully desensitized continued to tolerate one serving of milk
per day.53 The small number of patients that continue to consume
and tolerate CM after OIT is thought to be due to abdominal pain.
Safety and tolerability of OIT has remained challenging. Changes
in desensitization protocols based on individual patient character-
istics were reported in 2013, where patients with lower CM speciﬁc
IgE were desensitized faster.54 Other patient characteristics that
predict eventual tolerance include starting tolerant dose and
whether epinephrine/adrenaline is required during initial chal-
lenge.55,56 Other predictors of clinical reactivity to CM include
asthma, asthma requiring controller therapy, and allergy to more
than 3 foods.57 Laboratory characteristics that may predict safety
and efﬁcacy were reported by Martizez-Botas et al. in 2015.58 In
that study, a bioinformatics analysis selected two sets of 16 IgE
binding peptides at baseline that predicted safety and efﬁcacy. A
similarly structured mechanistic study reported that levels of spe-
ciﬁc IgA, IgG, IgG1 and IgG4 to CM and casein, and cow's milk-
speciﬁc IgE prior to OIT were higher in children who dis-
continued therapy due to adverse events than in those who ach-
ieved desensitization.56
Many patients undergoing CM OIT have achieved desensitiza-
tion, but clinical utility has been limited by adverse events.
Multifood OIT
For patients who have allergy to more than one food, multifood
OIT has been attempted. In a small phase 1 trial, multifood OIT was
comparable in safety to single food immunotherapy.59 Among 25patients, reaction rates of 3.3% and 3.7% were observed for multi-
food and peanut treated OIT patients respectively. Most reactions
were mild, and epinephrine/adrenaline was used twice in each
group. Efﬁcacy was examined, though not the primary endpoint,
and each group achieved target doses of foods in similar numbers,
though the multifood group taking longer temporally to reach
target dosing by design.
Multifood OIT has been examined using rush protocol with
addition of anti-IgE monoclonal antibody, omalizumab.60 Twenty
ﬁve patients with multiple food allergies were treated with oma-
lizumab for 8 weeks prior to and after rush desensitization in a
phase 1 trial. The rush protocol allowed doses of 1250 mg of food
protein on the initial day, which was successful in 19 of 25 subjects.
At 18 weeks, subjects reached an average of 4 g food protein per
allergen. Adverse reactions were comparable to other studies,
occurring in 5.3% of home doses, and 94% of reactions were mild.
For patients with allergy to multiple foods, these phase 1 studies
show promise.Anti-IgE adjunct therapy with OIT
Since food-speciﬁc IgE is largely responsible for allergic re-
actions to food, it follows that anti-IgE therapy may be a useful
adjunct for OIT. Omalizumabwas examined as a facilitator for rapid
oral desensitization in peanut allergic patients in 2013.61 While
there was no placebo arm, initial results were promising, with 12/
13 patients achieving rapid oral desensitization. Ultimately, pa-
tients who achieved desensitization were able to tolerate 4 g of
peanut ﬂour in a median time of 8 weeks. Adjunctive therapy with
omalizumab in children with multiple food allergies resulted in 16
week desensitization in 19/25 participants using multifood OIT, as
discussed above.60 Using omalizumab to facilitate rapid desensiti-
zation to cow's milk has also been reported.62 That pilot study re-
ported 9 of 11 patients rapidly desensitized to 1000 mg in one day.
Of note, one patient dropped out due to abdominal pain and the
other required epinephrine/adrenaline to reverse a severe reaction.
Use of anti-IgE may facilitate rapid desensitization, although
more rigorous placebo-controlled trials must be performed. While
initial studies are small, rates of adverse events seem similar to
conventional OIT.Safety of OIT
The primary limitation of OIT is safety (Table 3). Adverse events
requiring epinephrine/adrenaline administration are commonly
reported. One retrospective review reported that among 395 pa-
tients and 240,351 doses, 95 doses required epinephrine/adrena-
line administration due to a severe reaction.63
Other adverse reactions during peanut OIT are not uncommon.
Prospectively, one study reports that 3.5% of patients experience
mild upper respiratory symptoms or skin symptoms.64 It was re-
ported in that trial that risk of adverse reactions climbs higher with
several clinical predictors, including concurrent illness, poorly
controlled asthma, timing of dose after consumption of food,
physical exertion after dosing, and dosing during menses.64
Abdominal symptoms and less severe side effects occur at a
higher rate. Initial escalation of dosing was found to be associated
with abdominal symptoms in 68% of subjects.65 That trial also
found other adverse events: an 18% risk of mild wheezing on the
initial escalation day, and a 46% chance of having any symptoms
after a buildup dose. A larger trial examining OIT found that nausea
and vomiting occurred in 79.4% (31 of 39) of patients.15
Development of eosinophilic esophagitis (EoE) has been a feared
complication of OIT. A meta-analysis performed in 2014 reported
that EoE occurs in 2.7% of patients treated with OIT, although some
feel this is under-diagnosed.18
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clinical utility, and may include anaphylaxis, abdominal pain,
wheeze or development of eosinophilic esophagitis. The gastroin-
testinal allergic side effects are the most limiting to the use of OIT
presently.
Sublingual immunotherapy
As opposed to OIT, where patients consume the allergen of in-
terest, sublingual immunotherapy (SLIT) employs the use of a liquid
allergen extract, which patients place on the sublingual tissue.
These extracts have been used in the research setting only, and are
composed of the allergen suspended in a liquid or dissolving tablet.
The sublingual formulation is held in place by the patient for up to
several minutes before spitting out or swallowing the solution. SLIT
has been FDA approved for pollen allergy (ragweed and grass),
though SLIT remains investigational for foods. Indeed, no stan-
dardized products with known potency or shelf-life are available.
Peanut SLIT
The mechanism for inducing tolerance using SLIT has not been
completely elucidated. Patients receiving SLIT have shown
increased in salivary peanut-speciﬁc IgA compared to placebo.66
Changes in peanut speciﬁc salivary IgA correlated to total peanut
tolerated during DBPCFC, suggesting that IgA in saliva may have a
role in modulating systemic response.
In a multicenter RCT of peanut SLIT, Burks et al. found that over
98% of doses were tolerated without adverse reactions beyond the
oropharynx, and that epinephrine/adrenaline was not required for
any reaction.67 Desensitization to 10 g of peanut ﬂour was achieved
in 10.8% (4 of 37 patients), although 50% of subjects stopped ther-
apy or dropped out by the 3-year follow up. Eight weeks after
stopping SLIT, all 4 desensitized subjects achieved sustained un-
responsiveness. Favorable response to SLIT was in part predicted by
decreased peanut speciﬁc basophil activation and skin prick test
titration.
In an RCT to examine the efﬁcacy of 44-weeks of SLIT in peanut
allergy, Fleisher et al. reported desensitization in 14 of 20 subjects
(70%).68 Desensitized subjects were able to consume either 5 g or at
least a 10-fold increase in peanut powder during OFC, compared to
15% receiving placebo.
Comparison of OIT and SLIT has often come to similar conclu-
sions: OIT is more effective in desensitization, but accompanied by
more frequent and severe adverse events. In one retrospective
comparison of SLIT to OIT for peanut-allergic children, the authors
found OIT to have more signiﬁcant mechanistic impact, as changes
in peanut speciﬁc IgE and IgG4 were more pronounced.69 OIT pa-
tients were noted to be three times more likely to pass desensiti-
zation OFC when compared to patients after SLIT. In a SLIT versus
OIT prospective RCT, increased food challenge threshold was 141-
fold for OIT and 22-fold for SLIT.70 Adverse reactions were more
commonly seen with OIT: 43% of doses versus 9% for SLIT.
Milk SLIT
Milk SLIT was ﬁrst reported in 2006, where De Boissieu et al.
reported 8 patients undergoing 6 months of therapy and a 70%
desensitization rate, with 4 subjects eventually normalizing their
diet.71 A larger RCT is reported by Keet et al., with 30 children
receiving either SLIT or SLIT followed by low- or high-dose OIT.17 In
this trial, patients received 8 g milk protein challenges after 12 and
60 weeks of maintenance therapy. Of SLIT-only treated subjects, 1
of 10 passed the food challenge. Of subjects treated with SLIT fol-
lowed by low dose OIT, 6 of 10 passed. Of subjects treated with SLIT
followed by high dose OIT, 8 of 10 passed food challenges. After
cessation of SLIT or OIT, 6 of the 15 desensitized patients regainedreactivity, and two of those patients became reactive after only 1
week. As expected, the addition of OIT to SLIT led to improved ef-
ﬁcacy, but more systemic reactions were observed in OIT treated
groups.
In summary, peanut and CM SLIT shows promise as a form of
immunotherapy primarily for the safety proﬁle when compared to
OIT. Unfortunately, efﬁcacy of SLIT compared to OIT remains
limited. No trials regarding SLIT with egg allergy could be found.
One speciﬁc niche for SLIT may be for families or childrenwhose
goal is to avoid a life-ending reaction with very small, accidental
ingestion, with minimal risk of side effects, though further study is
warranted.
Epicutaneous immunotherapy
Epicutaneous, or patch immunotherapy (EPIT) studies are in
preliminary phases of study and have shown some promise.
Mechanistic mouse studies involving EPIT have shown induction of
T-regulatory cells, down regulation of the allergic response, and
prevention of new allergic sensitization.72e77 In 2010, ten CM
allergic children were randomized to receive a 48-hour CM-patch
three times per week for 3 months versus placebo in a pilot
study.78 An increasing trend in cumulative tolerated dose of cow's
milk from a mean of 1.7 mLe23 mL was shown. Skin irritation was
very common, reported in 50% of subjects. Severe reactions or
anaphylaxis were not reported.
In 2012, the Efﬁcacy and Safety of Several Doses of Viaskin
Peanut in Adults and Children with Peanut Allergy (VIPES) study
was initiated.79 VIPES is a multicenter, double-blinded placebo
controlled, phase IIb study of Viaskin peanut that has enrolled 221
peanut-allergic subjects in North America and Europe. Subjects
aged 6e55 were randomized into four treatment arms: placebo,
and one of three dosing groups (50,100 and 250 mg peanut protein).
Treatment success was deﬁned as being able to tolerate at least 1 g
of peanut protein or a 10 fold higher dose needed to elicit a reac-
tion. Success was seen in all three treatment groups (45.3%, 41.1%
and 50%, respectively). When treatment success was deﬁned more
strictly and perhaps more practically, as 10-fold improvement in
tolerance and a minimum of 1 g tolerance, success occurred in
28.6%, 30.8% and 32.1% in each treatment group respectively, and in
6.5% of placebo treated patients. No systemic reactions requiring
epinephrine/adrenaline were observed. This trial remains in prog-
ress to assess sustained unresponsiveness and is currently not in
press. EPIT remains a subject of intense study, and given the safety
proﬁle, this strategy holds much promise.
Non allergen speciﬁc therapies
Recombinant vaccine
In the experimental setting, the use of peanut protein using an
Escherichia coli capsule has been reported.80 In this study, the EMP
123 bacterial shell was built around Ara h1, 2 and 3, and rectally
administered to adult volunteers. Systemic reactions were
observed in over 50% of patients. Another recombinant protein U-
OMP16, using a Brucella species, was designed then studied in mice
in 2014.81 In the murinemodel, the recombinant vaccinewas found
to abrogate IgE mediated milk allergy in mice. While recombinant
vaccines certainly show promise, no acceptable safety or efﬁcacy
has been demonstrated in humans to date.
Chinese herbals
Food Allergy Herbal Formula 1 (FAHF-1), a Chinese herbal
mixture, has generated interest for the potential to dampen the IgE
Table 5
Key issues in active treatment of food allergy.
 OIT is highly efﬁcacious in achieving desensitization, but is limited by
frequent adverse events such as anaphylaxis and EoE.
 SLIT is less efﬁcacious than OIT, but more safely administered.
 EPIT is effective in inducing modest levels of tolerance with fewer adverse
events, although further study is warranted.
 Anti-IgE therapy, using omalizumab, may be a useful adjunct in desensitiza-
tion to have fewer allergic side effects.
 Probiotic adjunctive therapy with OIT has shown promise in an initial trial
(though that trial was not placebo-controlled)
 Goals of active treatment of food allergy may shift in the future: from com-
plete desensitization to providing modest levels of tolerance that would keep
patients safe in a small, accidental ingestion.
 Active prevention of food allergy using early introduction of peanut in high
risk infants will be an important strategy to reduce sensitization.
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FAHF-1 was found to prevent peanut anaphylaxis after 14 weeks of
administration.82,83 The proposedmechanism of action of FAHF-1 is
reduction of IL-4, IL-5 and IL-13 stimulation and reduction of
allergic response, which was demonstrated in vitro in mice.84
Amore speciﬁc formulation, FAHF-2 underwent a phase 1 safety
trial in 2010, and no adverse events were reported.85 A 2010 follow
up human study demonstrated suppression of basophil activation
with FAHF-2.86 More recently, FAHF-2 was used to treat three
children with a history of food allergy.87 After treatment for 1e2.5
years, all passed oral food challenge. The active ingredients
berberine and limonin have been proposed, both found in FAHF-
2.88 Without phase 2 studies, this Chinese herbal therapy for food
allergy, while fascinating, remains experimental.
On the horizon
A level of efﬁcacy has been demonstrated for OIT, SLIT and EPIT,
although an increase in adverse events has been associated with
improved efﬁcacy (Fig. 1). The future may incorporate different
methodologies including immunotherapy, monoclonal antibodies,
adjuvants and probiotics, as researchers ﬁne-tune their approach.
Animal models examining helminthes, DNA vaccines, and toll-like
receptor agonists are currently underway.89,90
Active prevention
With the startling growth in patients with food allergy, there
has been a concerted effort to focus on prevention. A landmark trial
reported in 2015 randomized 640 infants with severe eczema, egg
allergy or both (high-risk for peanut allergy) to consume or avoid
peanut until 60 months of age.91 Peanut allergy at 60 months was
seen in 13.7% of avoidant infants, and 1.9% of actively treated infants
(regularly consumed peanut). Early introduction of peanut
dramatically reduced the incidence of peanut allergy. This strategy
is further being explored, and active prevention with early intro-
duction of peanut is now recommended and determined to be
feasible.92
Conclusions
Immunotherapy remains the most promising hope for patients
with food allergy, who now rely on avoidance and carrying
epinephrine/adrenaline auto injectors in case of accidental expo-
sure (Table 5). Desensitization and sustained unresponsiveness
after IT (immunotherapy) have been demonstrated, but at a cost, asFig. 1. Efﬁcacy and safety have an inverse relationship as related to food immuno-
therapy. Oral immunotherapy (OIT) is most efﬁcacious in inducing desensitization,
while the highest rate of adverse reactions is observed, some of which are severe.
Sublingual immunotherapy (SLIT) and epicutaneous immunotherapy (EPIT) are
generally less efﬁcacious and associated with fewer total adverse events, none of
which have been severe.adverse events are common and can be severe. In the future, we
may see more modest desensitization goals; perhaps enough pro-
tection to safely tolerate an accidental bite of an offending food. For
families in whom the social/emotional impact is signiﬁcant, this
modest amount of desensitization may be dramatically relieving.
As studies continue, we will certainly learn more about complica-
tions that are not completely understood, such as EoE. We can
expect combinations of IT, monoclonal antibodies and adjuvants to
further assist researchers ﬁnd an efﬁcacious, safe product. And
while there currently exists no FDA-approved active treatment for
food allergy, there continues to be a vigorous search for a cure.
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